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The interplay between the immune response and the gut microbiota is complex. Although it is
well-established that the gut microbiota is essential for the proper development of the immune sys-
tem, recent evidence indicates that the cells of the immune system also inﬂuence the composition of
the gut microbiota. This interaction can have important consequences for the development of
inﬂammatory diseases, including autoimmune diseases and allergy, and the speciﬁc mechanisms
by which the gut commensals drive the development of different types of immune responses are
beginning to be understood. Furthermore, sex hormones are now thought to play a novel role in this
complex relationship, and collaborate with both the gut microbiota and immune system to inﬂuence
the development of autoimmune disease. In this review, we will focus on recent studies that have
transformed our understanding of the importance of the gut microbiota in inﬂammatory responses.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Regulation of the immune response by the gut microbiota
The commensal bacteria, or microbiota, colonizing the gut per-
forms several functions: it plays a critical role in the breakdown of
indigestible complex plant polysaccharides, synthesizes important
nutrients such as vitamin K, and provides an important layer of de-
fense against invasion by pathogenic microorganisms. Interest-
ingly, the intestinal microbiota affects the immune and/or
inﬂammatory status of the host by modulating intestinal barrier
function and by inﬂuencing the development of the immune re-
sponse. Several gut microbial structures that play an important
role in barrier functions have been identiﬁed. The secreted protein,
p40, from Lactobacilli LGG ameliorates cytokine-mediated apopto-
sis and disruption of the gut epithelial barrier [1], and ﬂagellin
from Escherichia coli Nissle is associated with induction of b-defen-
sin 2 in epithelial cells [2]. Gut microbiota has been shown to direct
maturation of the host immune system [3], to play a key role in the
induction of immunoglobulin (Ig) A [4,5] and germinal centers [6],
and to drive Th1, Th17, and regulatory T cell (Treg) development in
the gut [7–9]. In most individuals, the commensal-mediated
induction of these different components of the immune response
is beneﬁcial for host health. However, the composition of the gutmicrobiota can differentially inﬂuence various immune cell
populations and adversely affect autoimmune/inﬂammatory dis-
ease-susceptible hosts, e.g., the presence of segmented ﬁlamentous
bacteria (SFB) has been associated with a strong Th17 response and
development of Th17-mediated diseases [10–12].
Colonic commensal bacteria may ‘‘educate’’ both thymically
and peripherally-derived regulatory T cells. One study using mice
transgenic for T cells expressing a limited, but diverse [i.e., express
identical T cell receptor (TCR) b], TCR repertoire showed that the
TCR repertoire of colonic Tregs is unique (i.e., is not expressed by
thymically-derived Tregs) and reacts to bacterial isolates, suggest-
ing that encounter with gut commensal bacteria induces periphe-
ral generation of colonic Tregs, and thereby, tolerance to the gut
microbiota [13]. In contrast, a more recent study also using trans-
genic mice expressing a limited, but diverse, TCR repertoire (i.e.,
TCRmini mice) showed that thymic and intestinal Tregs share a
majority of dominant TCRs and many of these TCRs recognize
microbial antigens. Moreover, treatment of the TCRmini mice with
a cocktail of antibiotics that alters the composition of the gut mic-
robiota results in a concomitant change in the colonic thymic Treg
TCR repertoire. These results suggest that the repertoire of
thymus-derived Tregs is heavily inﬂuenced by the microbiota,
and thymus-derived Tregs may play a dominant role in maintain-
ing tolerance to gut commensal bacteria antigens [14]. The contra-
dictory results of these two studies make it difﬁcult to reach any
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populations, i.e., thymic-derived versus peripherally-induced, that
reside in the gut and mediate tolerance to components of the gut
microbiota. Other populations of regulatory cells also appear to
be activated/induced by commensal bacteria. A population of B
regulatory cells (Bregs) was identiﬁed in B6 mice whose gut bacte-
rial load was reduced by oral administration of a combination of
broad spectrum antibiotics [15]. Importantly, this Breg population
protected the animals from developing experimental autoimmune
encephalomyelitis (EAE). EAE protection by reduction of the
gut microbiota is associated with generally enhanced levels of
CD19+B220+ cells in the mesenteric/cervical lymph nodes
(LN) and spleen, increased percentages of a subpopulation of
CD19+CD5+ B cells in the mesenteric/cervical LN, and higher fre-
quencies of the CD1dhiCD5+ cell subset in the spleen/LN. Adoptive
transfer of splenic and LN CD5+ B cells isolated from antibiotic-
treated mice conferred better protection against EAE than CD5+ B
cells from untreated mice by inducing a shift from a Th1/Th17 to
a Th2-response [15] possibly through a mechanism involving IL-
10. Interestingly, reduction of the gut bacterial load by broad
spectrum antibiotics protects against EAE in different models via
induction of different populations of regulatory cells, e.g.,
IL-10-producing CD1dhiCD5+ Bregs are induced in B6 mice [15]
and IL-10-producing Tregs in SJL mice [16]. It is not clear why a
reduction in gut bacterial load would favor regulatory T and B cells
versus effector T cells. However, the antibiotics may not only
reduce the bacterial load, but they may also alter the microbial
composition, thereby, favoring commensal bacteria that induce
regulatory cells and/or eliminating commensal bacteria that
induce Th1/Th17 cells.
In the past several years, numerous reports have shown that an
alteration in gut microbiota can favor induction of effector T cells
over Tregs, and, consequently, trigger the development of autoim-
mune/inﬂammatory diseases (reviewed in [17]). Those studies
identiﬁed speciﬁc gut commensals that appear to induce either
Th17 or Treg responses that are associated with development or
protection from disease, respectively. The presence of segmented
ﬁlamentous bacteria (SFB) in the murine gut is associated with
induction of Th17-mediated autoimmune/inﬂammatory diseases,
such as colitis (induced by transfer of CD4+CD45RBhi cells into SCID
mice), arthritis and experimental autoimmune encephalomyelitis
(EAE) [10–12]. On the other hand, SFB protects from invasion by
the pathogenic microorganism, Citrobacter rodentium, by inducing
IL-22 production by Th17 cells that inhibits the growth of this
microorganism [9]. Similarly, SFB protects in an IL-17-dependent
manner against development of type 1 diabetes (T1D) in Non Ob-
ese Diabetes (NOD) mice [18], a spontaneous model of T1D. In this
case, SFB-induced Th17 cells are not involved in disease pathogen-
esis, but appear to be protective through a mechanism that in-
volves TGFb [19]. These data indicate that a given gut commensal
bacteria is not always beneﬁcial or detrimental, but can have dif-
ferential effects depending on the context. Furthermore, the pres-
ence of Clostridium leptum and coccoides bacteria, or colonization
of mice with the human commensal, Bacteroides fragilis (B. fragilis)
is associated with the induction of Tregs and prevention of dextran
sodium sulfate (DSS)-induced or 2,4,6-trinitrobenzene sulfonic
acid (TNBS)-induced colitis, respectively [7,20]. The speciﬁc mech-
anisms by which gut commensals induce Tregs are beginning to be
understood. As described below, molecules expressed or produced
by commensal bacteria, such as polysaccharide A and short-chain
fatty acids (SCFAs), modulate immunoregulation by acting directly
on Tregs or on dendritic cells (DC). In contrast, very little is known
about the mechanisms underlying the microbiota-mediated induc-
tion of CD5+ Bregs that protect against EAE [15], and the speciﬁc
commensal bacteria and molecules that trigger their induction re-
main to be identiﬁed. Moreover, although SFB colonization ofgerm-free mice triggers production of serum amyloid A (SAA) by
cells of the terminal ileum, and SAA induces lamina propria DC
to produce IL-23 and induce Th17 differentiation, the speciﬁc
molecules produced by SFB that trigger this response are also
unknown [9].
2. Speciﬁc interactions between commensal bacterial antigens
and pattern recognition receptors of the immune system
Host–microbe interactions establish immunological homeosta-
sis in the gut, and the molecular mechanisms underlying these
interactions are currently under study. Commensals interact with
the immune system via recognition of pathogen-associated molec-
ular patterns (PAMPs) by pattern recognition receptors (PRRs),
including toll-like receptor (TLR) and nucleotide-binding oligomer-
ization domain-containing protein (NOD), expressed by a variety of
host cells. The gut commensal bacteria are the source of peptido-
glycan that prime the innate immune response through the two
cytosolic PRRs, NOD1 and NOD2, expressed by intestinal epithelial
cells, paneth cells, macrophages and DC. NOD plays an important
role in controlling the immune response to commensal bacteria
as indicated by the fact that Nod1- and Nod2-deﬁcient mice exhibit
a weakened intestinal barrier to gut microbes due to decreased
production of the antimicrobial peptides, a- and b-defensins and
RegIII-gamma [21,22], and are more susceptible to DSS-induced
colitis [21]. Similarly, individuals with mutations in NOD2 exhibit
an increased susceptibility to Crohn’s disease [23,24], and
NOD1 polymorphisms are also associated with inﬂammatory bo-
wel disease (IBD) [25]. Interestingly, a mutation in NOD2 in Crohn’s
disease patients is associated with suppression of IL-10 transcrip-
tion in monocytes [26]. It is, therefore, possible that the failure to
control the bacterial burden in the gut in concert with a deﬁciency
in anti-inﬂammatory cytokines contribute to the generation of im-
mune responses against gut commensals, and the subsequent
intestinal inﬂammation in IBD patients. The speciﬁc mechanisms
by which commensals trigger the immune response, and subse-
quent disease are, however, unknown.
Bacteroides fragilis (B. fragilis), a human commensal, induces
Tregs and prevents development of TNBS-induced colitis [7,20].
The precise mechanisms underlying the induction of Tregs by B.
fragilis have begun to be understood, and involve polysaccharides
(summarized in Fig. 1a). B. fragilis prevents TNBS-induced colitis
in mice through polysaccharide A (PSA) which induces IL10-pro-
ducing Tregs [20]. PSA can enhance Treg function via TLR2 signal-
ing directly in Tregs [27]. B. fragilis can also release PSA in outer
membrane vesicles (OMVs), that are sensed by dendritic cells
(DC) via TLR2 resulting in upregulation of growth arrest and
DNA-damage-inducible protein (Gadd45a) on DC and an increase
in IL-10 production. These DC can subsequently induce Tregs
in vivo and prevent TNBS-induced colitis [28]. Oral administration
of PSA mediates protection against EAE in an IL-10-dependent
manner, and is associated with accumulation of CD103-expressing
DC and Tregs in the LN draining the central nervous system [29].
Altogether, these studies show that PSA from B. fragilis can activate
Tregs directly and/or endows DC with the ability to induce Tregs.
On the other hand, SFB is known to induce IgA [4,5] and Th17
cell [8,9] differentiation, however, the speciﬁc SFB molecules trig-
gering these effects remain to be determined. SFB may either acti-
vate B and T cells directly, or affect intestinal cells such as
epithelial cells or DC, and trigger their ability to induce IgA and
Th17 cell differentiation. Recent analysis of the whole genome of
SFB shows that SFB encodes four types of ﬂagellin, three of which
are recognized by TLR5 [30]. TLR5 expression is limited in the
mouse gut to intestinal epithelial cells (IEC) and CD11chiCD11bhi
lamina propria DC (LPDC). Interestingly, LPDC are critical for the
generation of IgA and Th17 cells in the lamina propria, and produce
Fig. 1. Gut commensal inﬂuence on the immune response. (A) The molecules
expressed and produced by commensals affect the inﬂammatory response and Treg
differentiation. (B) Dietary ﬁber inﬂuences the gut microbiota composition, and in
turn, the metabolites produced by commensals affect the inﬂammatory response
and Treg differentiation/accumulation, Aldha1: aldehyde dehydrogenase isoform
1A1; DC: dendritic cells; Gadd45a: growth arrest and DNA damage inducible alpha;
GPR: G-protein-coupled receptor; NLR4: NLR family CARD domain containing 4;
PSA-OMV: polysaccharide A-associated outer membrane vesicles; SAA: serum
amyloid A; SCFAs: short-chain fatty acids; TLR: Toll-like receptor; Treg: regulatory T
cells.
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mensal bacteria may be able to evade TLR5 detection, it is possible
that one or more of the ﬂagellins produced by SFB can interact with
TLR5 on LPDC or the cytosolic receptor NLRC4, and trigger the re-
lease of cytokines favoring Th17 cell differentiation. Since immune
responses to ﬂagellin(s) seem to be involved in colitis development
[32], it would be interesting to determine whether SFB manipu-
lated not to produce ﬂagellins can still induce IgA and Th17 differ-
entiation. In addition, the numbers of LP Th17 cells are decreased
in TLR9-deﬁcient mice indicating an adjuvant effect for commensal
bacterial DNA [33], and the potential involvement of SFB DNA in
this process.
3. Role of molecules produced by gut commensals in the
regulation of the immune response
Commensals produce various molecules, from metabolites to
immunomodulatory peptides and DNA, that could affect cells of
the immune system (summarized in Fig. 1a and b). Short-chain
fatty acids (SCFAs) that are metabolized by gut commensals and
inﬂuence Tregs have received considerable attention recently
[34–37]. Garret and colleagues were the ﬁrst to show that SCFAs
produced by commensals can regulate homeostasis of Tregs inthe colon [34]. Oral administration (in drinking water) of the
SCFAs, butyrate, acetate and propionate, in germ-free (GF) mice in-
creases Treg numbers in the colon, but not the lymphoid organs.
SCFAs appear to mediate their effect directly on colonic Tregs, since
Foxp3 and IL-10 expression and suppressive function increase after
culture with SCFAs in vitro or treatment in vivo. Moreover, propio-
nate enhances Treg proliferation in vitro, and affects colonic Tregs
via the G-protein-coupled receptor (GPR), GPR43, through inhibi-
tion of histone deacetylase (HDAC) and subsequent histone-H3
acetylation. The development of colitis in the CD4+CD45RBhi adop-
tive transfer model was ameliorated by oral administration of pro-
pionate (in drinking water), correlating with higher numbers of
colonic Tregs, and dependent on GPR43 expression in Tregs [34].
Interestingly, higher levels of propionate and acetate are produced
by Clostridium cluster XIV than B. fragilis [34], and may mediate the
ability of C. leptum and coccoides to induce Tregs [7]. Similarly, two
later studies published in the same issue of Nature provide further
evidence that SCFAs inﬂuence Treg differentiation and new insight
into the molecular mechanisms underlying the effects of butyrate
on Treg differentiation [35,36]. Rudensky and colleagues showed
that oral administration of butyrate through drinking water in
antibiotic-treated mice promoted conserved noncoding sequence
1 (CNS1)-dependent extrathymic differentiation of Tregs in the
spleen and LN, but not colon [35], whereas feeding mice butyrylat-
ed starch increased Tregs in the colon. Oral administration (in
drinking water) of propionate induces the new generation of sple-
nic and colon Tregs, whereas acetate only induces accumulation of
Tregs in the colon in a CNS1-independent manner (i.e., via expan-
sion of thymus-derived Tregs, not de novo generation of Tregs), but
not the spleen. Butyrate appears to mediate its effects, at least in
part, directly on T cells via acetylation of histone H3 at the Foxp3
promoter and CNS1 enhancer. Furthermore, butyrate, and to a les-
ser extent, propionate, endows dendritic cells (DC) with an in-
creased ability to induce Treg differentiation though enhanced
histone H3 acetylation in DC [35]. Ohno and colleagues showed
that butyrate preferentially induces colonic Treg differentiation,
even under Th1- and Th17-polarizing conditions, via enhanced his-
tone H3 acetylation at both the promoter and the conserved non-
coding sequences of the Foxp3 gene locus. They also showed that
feeding a butyrylated diet ameliorates colitis in the CD4+CD45RBhi
adoptive transfer model through the induction of colonic Tregs, i.e.,
Treg depletion abrogates protection [36]. Another study by Gana-
pathy and colleagues addressed the possibility that butyrate affects
Treg differentiation in the colon by activation of an GPR [37], since,
as discussed above, both propionate and acetate mediate their ef-
fects on colonic Tregs and the inﬂammatory response in DSS-in-
duced colitis, respectively, via GPR43 [34,38]. This group showed
that GPR109a signaling enables colonic macrophages and DC to in-
duce differentiation of Tregs and IL-10-producing T cells. More-
over, splenic DC treated with butyrate induce Treg differentiation
in a GPR109a-dependent manner via production of IL-10 and Ald-
h1a1 [37]. This is in contrast to the data from the Rudensky group
who did not ﬁnd a decrease in Treg induction when using DC from
GPR109a deﬁcient mice [35]. The reason(s) for the discrepancy be-
tween the two studies is not currently clear, but underscores the
complexity of the mechanisms of action of SCFAs. Butyrate has also
been shown to activate GPR41 expressed by immune cells, includ-
ing peripheral blood mononuclear cells (PBMC), neutrophils,
monocytes and DC [39], suggesting that butyrate may also act
through GPR41 expressed by colonic DC, and induce Treg differen-
tiation in the colon through this mechanism. In summary, these
studies show that SCFAs can differentially inﬂuence immunoregu-
lation at three different levels by: (1) acting directly on pre-exist-
ing colonic Tregs via histone acetylation through GPR activation;
(2) inducing naïve T cells to differentiate into Tregs via epigenetic
upregulation of the Foxp3 gene through histone acetylation; and
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tiation via histone acetylation or GPR activation. Taken together,
these studies suggest that the types and levels of metabolites
produced by commensal bacteria may directly affect the balance
between pro- and anti-inﬂammatory immune cells.
The precise molecules that mediate the ability of other gut com-
mensal bacteria, e.g., lactobacilli, to prevent autoimmune/inﬂam-
matory diseases, such as colitis and type 1 diabetes [reviewed in
[40]], remain to be identiﬁed. Interestingly, although lactobacilli
do not produce butyrate [41], a recent metabolomic study showed
that Lactobacilli plantarum produces small immunomodulatory
molecules, the immunomodulins (e.g., pyro-dipeptides), that exhi-
bit anti-inﬂammatory activity. For example, administration of
pyro-phenylalanine and pyro-tryptophan into mice suppresses
production of IFNc in spleen stimulated with LPS [42]. Further-
more, a recent study showed that the ability of commensal DNA
to stimulate immune responses appears to be species-speciﬁc
and inversely correlates with the frequency of immunosuppressive
motif-containing DNA [43]. Genomic DNA from Lactobacillus para-
casei failed to induce proinﬂammatory cytokines, such as IL-6, by
lamina propria DC, rather, it induces Treg conversion in vitro,
whereas DNA from E. coli or CpG oligodeoxynucleotide induces
proinﬂammatory cytokines. This difference is apparently due to
the increased frequency in the suppressive sequences, TTAGGG
and TCAAGCTTGA, in the DNA of all Lactobacillus species tested,
but not in E. coli.
As mentioned above, other gut commensals, such as segmented
ﬁlamentous bacteria (SFB), have been implicated in the develop-
ment of inﬂammatory/autoimmune diseases mediated by Th17
cells, including colitis, arthritis and EAE [10–12]. Several studies
have shown that SFB-induced differentiation of Th17 is likely to in-
volve mechanisms that are independent of TLR-, NOD- or ATP-sig-
naling [9,44,45], but involves secretion of serum amyloid A (SAA)
possibly by gut epithelium, and subsequent production of IL-23
by lamina propria DC [9]. However, the SFB molecules involved
in induction of Th17 cells remain to be identiﬁed. Speciﬁc
metabolites produced by SFB, such as SCFAs, may preferentially
induce SAA and mediate Th17 differentiation. Butyrate has indeed
been shown to induce SAA2 genes in intestinal epithelial cells [46].
Finally, DNA from SFB could have a paucity of immunosuppressive
motif-containing DNA, and may consequently, preferentially
promote intestinal immune effector cells rather than sustaining
Tregs.
It would be very informative in the future to more speciﬁcally
characterize the impact of various known gut commensals and
their components, i.e., surface molecules, DNA composition and
metabolites, on the cytokine proﬁle of various immune cells such
as Th1, Th2, Th17, B cells, Bregs, Tregs, DC and macrophages, in or-
der to deﬁne a pattern that could predict whether a particular com-
mensal, DNA and/or their particular metabolite ratios will induce
pro- or anti-inﬂammatory responses.
4. Inﬂuence of the immune response on the gut microbiota
Several studies examining whether and how the immune re-
sponse affects the gut microbiota composition using mice with
selective immune deﬁciencies have found that both innate and
adaptive immune cells appear to shape the composition of the
gut microbiota. The composition of the gut microbiota in CD45-,
Rag- and CD45Rag-deﬁcient mice differs from wild-type (WT)
mice. Furthermore, co-housing CD45-deﬁcient and WT mice re-
sults in alteration of the microbiota composition in WT mice
[47]. The data indicate that cells of the immune system inﬂuence
the gut microbiota composition. Some studies have shown that
cells of innate immunity inﬂuence the gut microbiota. Loss of Tbet
in Rag2 deﬁcient (TRUC) mice leads to the overproduction of TNFaby colonic DC in response to gut commensal bacteria, and gener-
ates a colitogenic microbial community [48]. TRUC mice exhibit
an increased Bacteroidetes to Firmicutes ratio, and a lower propor-
tion of Proteobacteria compared to Rag2 deﬁcient mice. Moreover,
Klebsiella pneumoniae and Proteus mirabilis recovered from fecal
samples of TRUC mice were found to elicit colitis in Rag2 deﬁcient
mice [49]. A recent study has implicated group 3 innate lymphoid
cells (ILCs) and the aryl hydrocarbon receptor (Ahr) in promoting
gut immunity and controlling the gut commensals. Aryl hydrocar-
bon receptor is expressed on ILCs and regulates their maintenance
and function, including IL-22 production [50]. Interestingly, Ahr
deﬁcient mice exhibit reduced levels of ILCs and IL-22, leading to
the uncontrolled expansion of SFB and a subsequent increase in
Th17 cells and colitis development [51]. This study suggests that
ILCs control SFB levels in the gut via production of IL-22.
Nucleotide-binding oligomerization domain-containing protein 2
(NOD2), an intracellular protein sensor for bacterial cell wall com-
ponents, also plays an important role in the temporal development
and composition of the gut microbiota. Indeed, several reports
have shown that Nod2-deﬁcient mice display an increased bacte-
rial load in their feces and terminal ileum that exhibit an altered
composition characterized by decreased diversity and richness. A
decrease in fecal Proteobacteria [52] combined with an increase
in both fecal and ileal Bacteroidetes and Firmicutes was observed
in Nod2-deﬁcient mice compared to theWTmice [52–54]. Interest-
ingly, the Bacteroidetes and Firmicutes load is also higher in biop-
sies taken from patients with Crohn disease that are homozygous
for SNP13, a NOD2 variant [54]. Moreover, the gut microbiota of
Nod2-deﬁcient mice predisposes these mice to the development
of DSS-induced colitis. The disease risk was transmissible to WT
mice conferred by cohousing WT with Nod2-deﬁcient mice, while
mitigated by transplanting the cecal homogenate from WT mice
into germ-free Nod2-deﬁcient mice [55]. These ﬁndings suggest
that NOD2 plays a role in shaping the gut microbiota into a protec-
tive bacterial community, although one recent study using F2 lit-
termates could not ﬁnd any differences (22). Furthermore,
colonic epithelial cells from mice deﬁcient in the inﬂammasome
component, NLRP6, produced lower IL-18 levels, resulting in in-
creased levels of TM7 phyla and Bacteroidetes (Prevotellaceae, in
particular) compared to WT mice. NLRP6 deﬁcient mice also devel-
oped colitis. Both the unique microbiota as well as the colitis could
be transferred by co-housing WT mice with NLRP6 deﬁcient mice
[56]. Finally, two studies found different effects of TLR5 on the
gut microbiota. One study showed that TLR5 deﬁciency alters the
gut microbiota by comparing TLR5 deﬁcient and WT mice [57],
whereas another study found no differences in the composition
of the gut microbiota in mice deﬁcient for MyD88, or TLR2, 4, 5,
or 9 compared to WT littermates [58]. The conﬂicting conclusions
of these two studies may be due to the fact that littermates were
not compared in the ﬁrst study. Microbiota drift has been observed
during long-term breeding of isolated mouse colonies. Therefore,
changes in microbiota composition between non-littermate WT
and deﬁcient mice could be attributed to maternal transmission
rather than to a deﬁcient immune response [58]. The use of litter-
mates should be favored when comparing the gut microbiota be-
tween different groups of mice. Nevertheless, taken together, the
data described above strongly suggest that the innate immune re-
sponse has an impact on the composition of the gut microbiota.
Several studies have shown that adaptive immunity also has an
inﬂuence on the gut microbiota. Using 16S rDNA deep sequencing,
one recent study showed that the composition of the gut microbi-
ota in Rag1-deﬁcient mice is signiﬁcantly different than that of
their WT littermates, largely driven by an increase in Firmicutes.
In contrast, MyD88/TRIF/ mice exhibit no differences in gut
microbiota composition compared to WT littermates [59]. This
study indicates that T and B cells are capable of modulating the
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activation-induced cytidine deaminase (AID) lack IgA and appear
to support abnormally high levels of SFB compared to AID+/+
littermates. The lack of IgA in AID/ deﬁcient mice is associated
with an expansion of SFB and subsequent B cell hyperplasia. Para-
biosis between AID/ and GFP Tg mice at 2 months of age, which
allows exchange of gut-primed IgA-producing B cells from GFP Tg
mice to AID/ mice, reestablishes bacterial homeostasis in the
small intestine by preventing the expansion of SFB [60]. In another
study, the levels of SFB in SFB-monoassociated scid/scid mice re-
main high through 70 days of age whereas they were detected at
very low levels in scid/+ pups. This difference appears to be
associated with the lack of both acquired maternal secretory IgA
in the milk from scid mothers and self-produced intestinal IgA,
and, therefore, a failure to eliminate SFB via an IgA-mediated
mechanism [61]. These data indicate that the ability to produce
IgA is critical for regulation of certain gut commensal bacteria,
especially SFB.
Altogether, it appears that the cells of adaptive and innate
immunity can affect the composition of the gut microbiota. The
fact that the gut microbiota and the immune response can
inﬂuence each other suggests that an intricate relationship exists
between these two entities. Therefore, further dissection of the role
that various immune cells/molecules play is very important
for understanding these interactions, and will be crucial for devel-
oping prevention and/or treatment strategies for inﬂammatory
diseases.
5. Interaction between hormones, microbiota
and autoimmunity
Many autoimmune diseases occur with a much greater preva-
lence in females than males, as indicated by a female to male inci-
dence ratio of 50:1 for Hashimoto’s disease, 9:1 for Sjogren’s
syndrome, 9:1 for systemic lupus erythematosus (SLE), 9:1 for
antiphospholipid syndrome, 4:1 for rheumatoid arthritis and 3:1
for multiple sclerosis [62]. Although sex hormones have been
shown to have an impact on immune cells and autoimmune dis-
eases, the microbiota is emerging as an important environmental
factor in the sex-based bias in autoimmunity. This is based on
two recent studies examining differences in microbiota between
female and male mice in the spontaneous NOD model of type 1
diabetes (T1D) in which female, but not male, mice develop high
incidence of disease. These two studies demonstrate that gut
commensals inﬂuence sex hormone levels in the host, that
sex hormones, in turn, inﬂuence the composition of the gut
microbiota and somehow the microbiota and sex hormones, spe-
ciﬁcally androgens, together collaborate to modulate the patho-
genic response, and ultimately, disease development in NOD
mice [63,64].
The ﬁrst study by Danska and colleagues showed that a direct
interaction exists between sex hormones and microbiota that has
a signiﬁcant impact on the development of T1D [63]. Unlike spe-
ciﬁc pathogen free (SPF) NOD mice, germ-free (GF) female and
male NOD mice develop converging disease rates with similar
kinetics that is due to both an increase in disease incidence from
historical rates in males and a, somewhat less pronounced, de-
creased rate in females. These data suggest that the sex-based bias
in disease development in NOD mice is driven by commensal bac-
teria, and that male-speciﬁc microbiota may play a protective role.
Moreover, SPF male mice exhibit higher serum testosterone levels
than GF males, suggesting that commensal bacteria differentially
regulate testosterone production, and provide a protective effect
mediated, at least in part, via microbiota metabolism of sex hor-
mones. Conversely, sex-speciﬁc differences in the composition of
the microbiota are found only after puberty, suggesting that sexhormones may affect the composition of the gut microbiota. More-
over, orally gavage of female NOD weanlings with the cecal con-
tents from 14 week-old males altered the composition of the
microbiota, increased the testosterone levels, and reduced insulitis,
levels of insulin-speciﬁc antibodies, and incidence of disease in the
female recipients. Interestingly, this protection from disease is
abrogated by treatment with ﬂutamide, an anti-androgen drug,
suggesting that the male microbiota confers protection via an in-
crease in testosterone available to the female recipients. Thus,
manipulation of the gut microbiota of T1D-prone NOD mice at an
early age may confer protection from the disease by altering sex
hormone levels. This paper provides evidence for a direct effect
of the microbiota on the levels of male hormones, which in turn
inﬂuence disease development/progression.
The second study by Yurkovetskiy and colleagues also showed
that microbiota and hormones interact, triggering protective path-
ways in NOD mice [64]. In this study the authors showed, using
high-throughput sequencing of 16S rRNA, that pre-pubertal female
and male NOD mice possess similar compositions of microbiota,
but the populations begin to diverge in male, but not female, mice
as they mature. In contrast, the composition of castrated male mice
remained very similar to females over time, further suggesting that
male sex hormones affect the composition of the gut microbiota.
Interestingly, reconstitution of GF NOD mice with the Enterobacte-
riacae family (found in abundance by sequencing in one experi-
ment) or SFB protects only male, not female mice, from
developing T1D, suggesting that these speciﬁc bacteria can provide
protection to males. Analysis of testosterone levels in GF, SPF and
monocolonized male mice showed that the speciﬁc bacteria that
protect males from developing disease, i.e., Enterobacteriacae and
SFB, also increased testosterone levels in these mice. Finally, anal-
ysis of the gene expression pattern in pancreatic lymph nodes re-
vealed differential expression of 40 genes in the SPF male (i.e.,
mice protected from disease) compared to GF male and female,
and SPF female (i.e., all three develop disease) mice. The IFNc
and IL-1b pathway signatures are upregulated in SPF male mice,
and an analysis of several studies previously published by other
laboratories show that male NOD mice lacking IFNc, IFNc receptor,
or IL-1b develop disease rates compared to female NOD mice, and
strongly suggest that IFNc and IL-1b-mediated signaling may be
needed for protection of male mice from disease. Additionally,
the authors compared the expression pattern in pancreatic lymph
nodes (LN) from SPF NOD mice of 40 differentially expressed genes
using a meta analysis of data from 96 different cells/tissues, and
found that this pattern is most consistent with the macrophage–
monocyte lineage. Moreover, pancreatic LN (more speciﬁcally
CD4 and CD8 T cells) from SPF male mice exposed to SFB produce
more IFNc and IL-1b compared to female or castrated SPF male
mice that may be driven by microbiota-activated macrophages.
Taken together, these two studies show that signals from both
the microbiota and androgens modulate immune cells, and to-
gether they mediate the sex-based bias in T1D seen in NOD mice
[63,64]. With regard to the molecular mechanisms mediating pro-
tection in male NOD mice, IFNc seems to be a key molecule in-
volved, but its mechanism of action is unclear and requires
further investigation. However, T1D is not a sex-biased disease in
humans, whereas the prevalence of systemic lupus erythematous
(lupus) is much greater in women than men (9:1). The
(NZBxNZW)F1 (BWF1) mouse model of lupus exhibits the same fe-
male sex bias as that found in humans. Female, but not male, BWF1
mice develop the disease, and we have preliminary data indicating
that, similar to the pattern found in NOD mice, the composition of
gut microbiota in BWF1 male mice differed signiﬁcantly from that
of mature, but not peripuberal, female mice (data not shown).
These data suggest that androgens have an impact on gut
microbiota composition in lupus-susceptible mice, and as shown
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tective. Moreover, these data may indicate that unlike men, wo-
men that are genetically predisposed to develop lupus may
possess gut microbiota that fail to protect them against disease
development. In the future, it will be important to determine the
speciﬁc mechanisms and/or molecules produced by gut commen-
sals that are affected by, and affect, androgens, and are involved
in protection from sex-biased diseases such as lupus. This under-
standing will allow the development of novel strategies to prevent
and/or treat sex-biased autoimmune diseases.
6. Inﬂuence of the gut microbiota on inﬂammatory diseases
Studies in animal models of autoimmunity suggest that the gut
microbiota composition may determine whether a genetically sus-
ceptible individual will develop inﬂammatory/autoimmune dis-
ease (reviewed in [17]). Segmented ﬁlamentous bacteria (SFB) is
implicated in Th17-mediated diseases in animal models of arthri-
tis, experimental autoimmune encephalomyelitis (EAE), colitis
[10–12], and has been shown to exacerbate experimental asthma
[65]. However, SFB can protect against type 1 diabetes (T1D) [18]
and from invasion by C. rodentium [9]. B. fragilis, and Clostridium
and Lactobacillus species appear to be protective in animal models
of EAE, colitis, arthritis, T1D and asthma [7,20,66–69]. Although
dividing gut bacteria into ‘‘beneﬁcial’’ and harmful bacteria may
be an oversimpliﬁcation of the role of microbes in the gut, accumu-
lating evidence suggests that alterations in the gut microbiota
composition, frequently referred to as dysbiosis, are associated
with the development of allergies and inﬂammatory/autoimmune
diseases, including inﬂammatory bowel disease (IBD), rheumatoid
arthritis (RA) and T1D, in humans and animal models of disease
(Table 1).
6.1. Allergic disorders
Several studies have found that infants with food allergies and
eczema exhibit alterations in the relative levels of ‘‘beneﬁcial’’
and potentially harmful bacteria compared to healthy infants. For
example, the levels of the lactobacilli and biﬁdobacteria are lower,
while levels of coliforms and Staphylococcus aureus are higher in
the fecal samples from children with allergies to egg or cow’s milk
[70]. Infants with atopic eczema also have decreased levels of bif-
idobacteria and Enterococcus in their feces [71], but increased Clos-
tridium [72]. Along these lines, a recent study showed that early
lactobacilli colonization (at one week of life) appears to correlate
with a decreased risk for allergy at ﬁve years of age [73]. These
studies corroborate previous reports indicating that oral treatment
with lactobacilli improves allergy [74–77]. Similarly, the gut mic-
robiota also appears to be involved in asthma development. A pro-
spective birth cohort study comparing the fecal composition at
3 weeks of age and respiratory symptoms at 6 and 12 months of
age reveals an association between antibiotic use, high levels of
anaerobic bacteria and wheezing during the ﬁrst year of life, while
high levels of Clostridium species, in general, are protective [78].
However, another study shows that Clostridium difﬁcile coloniza-
tion in 1 month-old infants is associated with the eventual devel-
opment of asthma at 6–7 years of age [79]. Taken together, these
data suggest that speciﬁc species of intestinal commensal bacteria
may play either a pathogenic or protective role in the development
of allergies occuring in the gut or at sites distant from the gut, such
as the lung and skin.
6.2. Inﬂammatory bowel disease
The inﬂammatory bowel diseases (IBD), Crohn’s disease (CD)
and ulcerative colitis (UC), differ from classical autoimmunedisorders in that they reﬂect a disordered host response against
the intestinal microbiota, rather than a true autoimmune reaction
against a self protein [80]. IBD is thought to arise from an abnormal
immune response to components of the intestinal microbiota [81].
A spectrum of alterations in the gut microbiota is well described in
IBD patients, including increases in E. coli [82,83] and lower levels
of speciﬁc types of Bacteroides [84,85] and Firmicutes [86–88], in
particular, Faecalibacterium prausnitzii (F. prausnitzii) from the
Clostridia class and Firmicutes phylum [82,88] compared to
healthy controls. Although a particular etiologic agent has not been
found to date, a subset of CD patients was found to harbor a poten-
tially proinﬂammatory strain of adherent-invasive Escherichia coli
(E. coli) in their small intestine [89]. In a recent study, Biﬁdobacte-
rium was found to be increased in biopsies of active UC while Lac-
tobacilluswas increased in biopsies of active CD patients compared
to healthy controls, and F. prausnitzii was decreased in both feces
and biopsies of UC and CD patients [90]. Although treatment with
antibiotics may beneﬁt patients with IBD, two studies indicate that
antibiotic treatment early in life may increase the risk of IBD
[91,92]. Altogether, these data suggest that gut commensals can
play either a pathogenic or protective role in IBD.
6.3. Rheumatoid arthritis
Rheumatoid arthritis (RA) patients treated with minocyline, a
broad-spectrum antibiotic, exhibit signiﬁcant disease improve-
ment [93]. Moreover, alterations in the gut microbiota have been
demonstrated in patients with early RA [94,95]. One study compar-
ing fecal samples from early RA patients to patients with ﬁbromy-
algia showed that biﬁdobacteria and B. fragilis are decreased in the
gut of RA patients [94], suggesting that alterations in the abun-
dance of these two commensal species may inﬂuence the patho-
genesis of the disease. Interestingly, another study identiﬁed
Prevotella copri (P. copri) as a potential inducer of RA [95]. Indeed,
the authors found alterations of the gut microbiota in untreated
newly diagnosed RA patients compared to healthy individuals that
is characterized by an enrichment in P. copri and a decreased abun-
dance of Clostridium XIV and Bacteroidetes. These data suggest that
commensal bacteria may also play either a pathogenic or protec-
tive role in RA.
6.4. Type 1 diabetes
Studies in animal models of type 1 diabetes (T1D) have identi-
ﬁed associations between disease development and changes in the
gut microbiota [96–98]. Translating this observation into a clinical
context, four recent studies in humans show that the composition
of the gut microbiota may be altered in individuals at high risk of
developing T1D, i.e., those who express high-risk HLA alleles and
have at least two different diabetes-associated autoantibodies in
their serum [99–102]. The ﬁrst observation came from a cohort
of Finish children with high-risk HLA for T1D, where fecal samples
from subjects seropositive for two autoantibodies were compared
to seronegative controls (referred to as healthy) [99]. Pyrosequenc-
ing of the stool microbiota 16S rRNA revealed that Bacteroidetes
sequences increase over time while Firmicutes sequences decrease
in the children with autoantibodies, whereas the pattern was re-
versed in the healthy controls. Interestingly, Clostridium species
and B. fragilis are decreased in stool samples from seropositive chil-
dren.Moreover, the microbiome from seropositive children tended
to have decreased bacterial diversity and reduced stability over
time [99]. In a second study, the same group found that buty-
rate-producing bacteria are decreased in the seropositive children
[100]. Two subsequent larger studies that also analyzed pyrose-
quencing of fecal samples from seroconverted and healthy children
matched for age, sex and HLA-DQB1 genotype (high-risk for T1D)
Table 1
Changes in microbiota composition associated with allergy and inﬂammatory/
autoimmune diseases in patients and corresponding animal models.
Microorganism(s) Disease(s) References
Asthma/allergies
SFB Asthma [65]
Lactobacilli/biﬁdobacteria
Coliforms/Staphylococcus
aureus
Egg/milk allergies [70]
Biﬁdobacteria/Enterococcus Atopic dermatitis/eczema [71]
Clostridium Atopic dermatitis/eczema [72]
Lactobacilli Allergy [73–77]
Clostridium species Asthma [78]
Clostridium difﬁcile Asthma [79]
Lactobacilli Allergy/asthma (mouse) [115]
Clostridium leptum Asthma (mouse) [116]
Inﬂammatory diseases
Escherichia coli IBD (CD and/or UC patients) [82,83,89,108]
Bacteroides IBD (UC-CD patients) [84,85]
Firmicutes IBD (UC-CD patients) [86–88]
Firmicutes prausnitizi IBD (UC-CD patients) [82,88]
Biﬁdobacteria
Firmicutes prausnitizi
IBD (UC patients) [90]
Lactobacillus
Firmicutes prausnitizi
IBD (CD patients) [90]
Firmicutes prausnitizi TNBS-colitis (mouse) [112]
SFB CD45RBhi-colitis (mouse) [11]
Prevotella copri DSS-colitis (mouse) [95]
Autoimmune diseases
Biﬁdobacteria/Bacteroides
fragilis
RA vs ﬁbromyalgia patients [94]
Prevotella copri
Clostridium XIV/
Bacteroidetes
RA patients [95]
SFB RA, EAE (mouse) [10,12]
SFB T1D (NOD mouse) [18]
Bacteroidetes
Firmicutes
High risk T1D patients [99,101,102]
Clostridia/Bacteroides fragilis High risk T1D patients [99,101,102]
CD: Crohn’s disease; DSS: dextran sodium sulfate; EAE: experimental autoimmune
encephalomyelitis; IBD: inﬂammatory bowel disease; NOD: non-obsese diabetes;
RA: rheumatoid arthritis; SFB: segmented ﬁlamentous bacteria; T1D: type 1 dia-
betes; TNBS: trinitrobenzene sulfonic acid; UC: ulcerative colitis.
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levels of bacteria from the Bacteroidetes phylum and the Bacteroi-
des genus combined with lower levels of butyrate-producing bac-
teria, including members of Clostridium clusters IV and XIVa that
are associated with Treg induction in mice [7] and anti-inﬂamma-
tory properties, are found in seroconverted children.
6.5. Systemic lupus erythematosus
The relationship between systemic lupus erythematosus (SLE)
and the gut microbiota is still not well-characterized. One study
showed that germ-free lupus-prone NZB mice fed an antigen-free
diet exhibit less renal disease, while another study ﬁnds that
germ-free NZB mice have lower IgG levels, but higher anti-nuclear
antibodies (ANA) [103,104]. We have found that feeding of Lacto-
bacillus reuteri to B6Sle.123 and (NZBxNZW)F1 mice (two sponta-
neous mouse models of SLE) prevented lupus development,
increased survival, and increased the levels of peripheral Tregs
(data not shown). Since levels of Tregs are impaired in both
B6Sle1 and (NZBxNZW)F1 mice [105,106], there is a possibility
that administration of lactobacilli provided protection by modify-
ing the gut microbiota composition towards one that favors Treg
induction. The immunosuppressive motif-containing DNA ex-
pressed by lactobacilli could also affect Treg induction directly as
shown previously [43]. Finally, immunomodulins produced bylactobacilli could potentially inﬂuence Tregs and enhance their
ability to control effector cell responses [42]. To date, no analysis
of the gut microbiota of SLE patients has been performed. It would
be particularly interesting to compare the microbiota composition
in lupus patients that are in disease remission versus patients with
active disease to determine whether lupus ﬂares are associated
with variations in particular gut commensals.
6.6. What does it all mean?
The studies described above indicate that alterations in the gut
microbiota are associated with development of many allergic dis-
orders and inﬂammatory/autoimmune diseases. The mechanisms
underlying the impact of the microbiota on disease outcome are
not yet understood, but appear to involve increases or decreases
in various gut commensals that may be more conducive to patho-
genic or protective responses, most likely in the context of genetic
susceptibility. Although SFB is associated with induction of a num-
ber of diseases in mice, its relevance to human disease is in ques-
tion. A recent study did not detect evidence of the SFB genome in
the MetaHIT database (largest database for metagenomics of the
human intestinal tract) or the Human Microbiome Project metage-
nomic database, suggesting that SFB is either not present or is be-
low the detection level in humans [107]. Identifying an analogous
gut commensal in humans that may trigger a pathogenic immune
response responsible for disease development may provide the ba-
sis for novel therapies. However, many gut commensals appear to
be associated with an increase in inﬂammatory/autoimmune and
allergic diseases (Table 1). A Prevotella species such as P. Copri is
elevated in untreated newly diagnosed RA patients, suggesting that
this commensal could potentially induce disease. This is corrobo-
rated by experiments in mice showing that oral gavage of antibi-
otic-treated mice with P. copri exacerbates DSS-induced colitis
[95], suggesting that a Prevotella-enriched microbiome has the ten-
dency to support inﬂammation. Adherent-invasive E. coli (AIEC) are
present in the intestinal mucosa of CD and UC patients, but not
healthy patients [83,89,108]. AIEC isolated from IBD patients are
able to invade epithelial cells [109] and survive in macrophages
within autophagosomes [108–110]. Moreover, AIEC can induce
macrophages to produce high levels of IL-6, TNF-a, and IL-1b via
NLRP3-inﬂammasome [108]. Since CD patients exhibit lower
expression of NLRP3 [111], there is a possibility that a weak innate
inﬂammatory response is generated early in the disease process in
IBD patients, resulting in impaired clearance of AIEC and chronic
inﬂammation.
Decreases in Clostridium species, B. fragilis and butyrate-produc-
ing bacteria appear to be common to many inﬂammatory/autoim-
mune diseases (Table 1), i.e., T1D, IBD, and RA. The decrease in F.
prausnitzii found in IBD patients is of interest because this bacteria
is butyrate-producing, and its oral administration reduces the
severity of TNBS-induced colitis in mice [112]. It is possible that
decreases in these types of gut microbiota results in the impair-
ment of Tregs, since the types of commensals, or their metabolites,
that are decreased [34–36] have been associated with Treg induc-
tion in animal models [7,27]. Therefore, the defect in immunoreg-
ulation observed in T1D patients [113,114] may be tied to
alterations in the composition of gut microbiota, since certain bac-
teria [7,20] and their metabolites associated with Treg induction
[34–36] are decreased in individuals that seroconvert (T1D).
C. leptum, lactobacilli and biﬁdobacteria appear to be ‘‘beneﬁ-
cial’’ for allergy, since there is an inverse relationship between al-
lergy manifestation and the levels of these gut commensals
(Table 1). Although the mechanisms behind the protection are
unknown, a recent study reported that oral exposure of adult mice
to house dust induces Lactobacillus enrichment of their gut micro-
biota, and leads to a decreased Th2 response against allergens in
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via induction and/or activation of Tregs, since oral feeding of C. lep-
tum in mice increases Treg numbers in spleen and mediastinal LN,
and attenuates allergic airway inﬂammation [116]. Taken together,
these studies indicate that the gut microbiota can affect sites, in
this case the respiratory system, distant from the gut. One postu-
lated mechanism by which gut commensals mediate their effect
at distant sites is through production of SCFAs that can be found
in the circulation of the host upon fermentation of dietary ﬁber
[117]. Mice fed a high-ﬁber diet have increased circulating levels
of SCFAs and are protected against allergic airway disease. Further-
more, treatment of mice with propionate enhances bone marrow
hematopoiesis of DC precursors that eventually seed the lung,
but are unable to activate Th2 effector cells, thereby preventing
the development of allergic inﬂammation of the airways [117].
Since treatment of mice with butyrate inﬂuences systemic Treg dif-
ferentiation [35], SCFAs may mediate their immune modulating ef-
fects at distant sites via induction of Tregs. And since many species
of gut commensals produce SCFAs with the same structure, the
only differences among commensals is likely to be the quantity
of each type that is produced.
In patients with established allergic and inﬂammatory/autoim-
mune disease, it is difﬁcult to determine whether changes in mic-
robiota composition are a consequence or a cause of the disease.
Disease concordance in many autoimmune diseases is 30–50% in
monozygotic twins indicating that both genetic and environmental
factors govern development of disease, and therefore, alterations in
gut microbiota could play an important role. In individuals at high-
risk of developing T1D, changes in microbiota can be detected be-
fore disease onset (i.e., elevated glucose), but concomitant with the
production of autoantibodies, suggesting that components of the
microbiota may have an impact on the immune response and pro-
gression to full-blown disease. On the other hand, the inﬂamma-
tory response that leads to the production of autoantibodies may
also affect the gut microbiota. Interventional studies in humans
via manipulation of the gut microbiota through the use of probio-
tics [118,119] or fecal transplants [120,121], have had a positive
impact on disease status in IBD patients, and treatment with pro-
biotics improves allergic disorders [74–77]. These ﬁndings, at least,
suggest that the gut microbiota can be altered to have a positive
impact on these types of disease.
Finally, the fungal and viral components of the microbiome
should not be ignored, since these microorganisms have also been
shown to interact with the immune system and inﬂuence heath
and disease in mouse models of colitis [122,123]. A relationship
between the immune response and the human virome has been
identiﬁed, as indicated by increases in the total viral load of the hu-
man virome during immunosuppression of transplant patients, but
not in the bacterial microbiome [124]. The molecules responsible,
as well as the precise mechanisms of action, mediating changes
in the fungal and viral components of the microbiome, and subse-
quent effects on the immune response and disease development
remain to be assessed. This knowledge will not only help us under-
stand their contribution to disease susceptibility, but also aid us in
the development of novel therapies.
7. Using gut microbiota or its components in therapies for the
treatment of autoimmunity and allergy
Human gut microbiota, i.e., speciﬁc commensal bacteria or total
fecal transplant, is a new class of therapeutics under consideration
for the prevention and/or treatment of inﬂammatory diseases. Fe-
cal transplant is already used as a salvage treatment for C. difﬁcile,
and has been shown to be the most effective treatment for recur-
rent infection [121]. Two groups have developed a synthetic stool
mixture [125] and a capsule containing donor bacteria, i.e., a fecalpill [126], that are currently under study for treating this clinical
condition. A systematic review of the literature concerning the
use of fecal transplantation for the treatment of IBD was performed
in 2012. While 17 articles were found, nine were small case studies
of patients receiving fecal transplants for the management of IBD
or for the treatment of infectious diarrhea in IBD, and none were
conducted as controlled clinical trials [120]. The majority of pa-
tients (15/24) treated for their IBD underwent disease remission
without side effects [120], suggesting that fecal transplants may
represent a safe alternative treatment for IBD. Since then, two pilot
studies of fecal transplant in children with IBD have been con-
ducted, with one showing remission in 7 out of 10 patients with
Crohn’s disease [127], while the second demonstrated that 3 out
of 9 children with ulcerative colitis (UC) experienced remission
one week following the administration of fecal enemas [128]. Fi-
nally, a third study evaluated the impact of fecal transplant on
IBD in 5 adult patients with active UC refractory to standard ther-
apy and the corresponding temporal inﬂuence on gut microbial
communities. Only one patient exhibited an improved clinical
score, but he did not achieve remission. At 12 weeks post-trans-
plantation, his gut microbiota was similar to the donor, including
donor-derived SFCA-producing F. prausnitzii, Rosebura faceis and
Bacteroides ovatus [129]. In contrast, the microbiota of the other
patients were very different, including underrepresented phyla
(Bacteroidetes, Firmicutes and Verrucomicrobia) and an abun-
dance of Enterobacteriaceae and Lacnospiraceae [129]. Contrasting
results between pediatric and adult studies suggest that early
intervention may be more beneﬁcial. Furthermore, the identiﬁca-
tion of predictive markers for disease development may provide
a window of opportunity to intervene with preventative strategies
to prevent the development of active disease. In the case of individ-
uals at risk for developing T1D, high-risk HLA expression and sero-
positivity can be used as predictive markers. Preventative fecal
transplants from healthy relatives to high-risk individuals exhibit-
ing signs of microbiota alterations could potentially protect the lat-
ter from developing T1D. One could envision that similar
procedures could be performed for other autoimmune diseases
associated with altered microbiota, such as rheumatoid arthritis
[94], SLE and multiple sclerosis. After excluding the presence of
gut associated pathogens, the use of gut commensal bacteria has
been considered to be generally safe. However, there have been
some safety concerns, including the development of transient sys-
temic toxicity [129] or even sepsis using live bacteria in the case of
immunocompromised and/or severely ill patients. Patients who
contract C. difﬁcile under these acute conditions are the most likely
to need salvage therapy, often failing multiple antibiotic therapies.
We have safely administered transplanted stool from a pre-
screened family member under these clinical conditions, providing
life saving results. In our experience, no short-term sequellae have
been encountered to date (data not reported). However, in long-
term clinical disorders, such as UC, CD or other inﬂammatory/auto-
immune disorders the direct use of prebiotics or metabolites from
commensal organisms may be safer and more effective. Indeed,
oral administration of acetate ameliorates DSS-induced colitis in
mice [38] and Lactobacillus rhamnosus GG supernatant has been
shown to improve intestinal barrier function, protecting against
the development of alcoholic liver disease [130,131]. Finally, sev-
eral trials have used prebiotics, food ingredients that stimulate
the growth/activity of commensal bacteria, to treat or maintain
remission of IBD. Those prebiotics included ﬁber from Plantago
Ovata (PO) seeds [132], germinated barley food-stuff (GBF, a by-
product of the brewing industry) [133,134], and oat bran, i.e., all
forms of dietary ﬁber which ferment into SCFA. These therapies
have demonstrated promise as IBD treatments through their ability
to maintain remission of UC. Interestingly, treated patients in one
trial demonstrated elevated SCFA stool levels [135]. Future studies
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and allergic diseases should be conducted to determine the effec-
tive bacterial components, avoiding the negative impact of treating
with live bacteria. However, we should keep in mind that commen-
sal metabolites that are effective for IBD may not be effective for
other diseases. From a clinical standpoint, efforts to modulate the
enteric and other mucosal ﬂora offer an attractive alternative to
pharmacologic interventions focused on altering the immune sys-
tem. Current therapies taking broad swipes at the intact immune
system have unintended consequences, such as opportunistic
infections, activation of autoimmune events, or even induction of
malignancies. Finally, the identiﬁcation of susceptibility genes
and other biomarkers for early disease detection offer the ability
to target individuals in a pre-clinical phase of disease. If microbiota
manipulation through prebiotics, probiotics, or fecal transplant is
conﬁrmed to be safe, this treatment modality may offer a preven-
tative solution to hold off or reduce the severity of a host of
inﬂammatory/autoimmune disorders.
8. Concluding remarks
A number of studies suggest that alteration in the gut microbi-
ota may be responsible for the development of multiple inﬂamma-
tory diseases through the creation of an imbalance between
pro-inﬂammatory and anti-inﬂammatory/regulatory immune
cells. Although the speciﬁc molecules produced by commensal
bacteria that trigger inﬂammatory responses in the gut are still
not well-characterized, a number of microbiota-associated
molecules, including surface molecules such as PSA from B. fragilis
and metabolites such as SCFAs produced by a wide variety of gut
commensals including Clostridia, are now known to regulate
inﬂammatory responses through the induction of Tregs. Moreover,
immunomodulins produced by and immunosuppressive DNA se-
quences present in lactobacilli have been shown to mediate immu-
noregulation. Accumulating evidence suggests that SFB is a critical
component of the microbiota that drives disease development in a
number of Th17-mediated mouse models of inﬂammatory/autoim-
mune diseases, and determining whether the human microbiota
contains a homologous microbe with similar function should be
a major focus of future work. Moreover, it will be critical to deter-
mine how SFB, or the potential human homologous commensal(s),
induce Th17 cells, including the cells and molecules involved, in
order to develop novel strategies for the prevention and/or treat-
ment of Th17-mediated diseases. Androgens have also recently
been identiﬁed as part of the picture, since they can both affect
the gut microbiota and be affected by them. Future work aimed
at characterizing, in detail, the impact of commensal by-products
on the immune and hormonal systems, not only in the gut but at
distant mucosal sites, will be crucial for developing therapies for
diseases associated with altered gut microbiota. Furthermore,
understanding the environmental factors and the genetic inﬂu-
ences that shape the composition of the gut microbiota will be
important for the development of strategies geared toward manip-
ulating the microbiota of individuals at risk for developing disease.
Although the gut microbiota appears to play an important role
in controlling both gut speciﬁc as well as distant immune re-
sponses [10,117,136], understanding the role that local microbiota
plays on local immunity and subsequent disease that can result
from alterations in microbiota at the site is vitally important. Naik
et al. have demonstrated that resident commensal bacteria in the
skin controls the local immune response in a manner similar to
that previously described in the gut [137]. This concept is likely
to apply to all mucosal sites, and implies that alteration in the local
microbiota may play a role in various diseases. Analysis of the
microbiome at sites other than the gut in healthy versus sickindividuals will, therefore, be critical in order to gather information
about the interaction of resident commensals and the immune re-
sponse at local sites. This will aid in the design of novel therapies
aimed at reestablishing a protective local microbiota, and treating
pathogenesis resulting from an alteration in the microbiota. Cus-
tomized therapies directed at recolonization of speciﬁc sites with
particular beneﬁcial commensals or their by-products certainly
seems to be the wave of the future.
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